Abstract
Several morphological and functional imaging techniques are usually used to detect residual/recurrent medullary thyroid carcinoma (MTC) with variable results; currently, there is growing interest in positron emission tomography (PET) methodology. Herein, we report our experience of and a literature review about the comparison of different positron emission tomography (PET) tracers in patients with residual/recurrent MTC. 18F-DOPA PET/CT seems to be the most useful imaging method to detect recurrent MTC lesions, performing better than 18F-FDG and 68Ga-somatostatin analogs PET/CT. 18F-FDG may complement 18F-DOPA in patients with aggressive tumors. 68Ga-somatostatin analogs PET/CT may be useful to select patients who could benefit from radioreceptor therapy. The information provided by the various PET tracers reflects different metabolic pathways, and may help to select the most appropriate treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams S, Baum RP, Hertel A et al (1998) Metabolic (PET) and receptor (SPET) imaging of welland less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun 19:641–647
Ambrosini V, Marzola MC, Rubello D et al (2010) (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 37:46–48
Beheshti M, Pöcher S, Vali R et al (2009) The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol 19:1425–1434
Beuthien-Baumann B, Strumpf A, Zessin J et al (2007) Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 34:1604–1609
Bodei L, Handkiewicz-Junak D, Grana C et al (2004) Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 19:65–71
Castellucci P, Pou Ucha J, Fuccio C et al (2011) Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med 52:886–890
Conry BG, Papathanasiou ND, Prakash V et al (2010) Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 37:49–57
Hoegerle S, Altehoefer C, Ghanem N et al (2001) 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64–71
Jang HW, Choi JY, Lee JI et al (2010) Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT. Endocr J 57:1045–1054
Kebebew E, Ituarte PH, Siperstein AE et al (2000) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139–1148
Koopmans KP, de Groot JW, Plukker JT et al (2008) 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 49:524–531
Marzola MC, Pelizzo MR, Ferdeghini M et al (2010) Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging. Eur J Surg Oncol 36:414–421
Pacini F, Castagna MG, Cipri C et al (2010) Medullary thyroid carcinoma. Clin Oncol 22:475–485
Pałyga I, Kowalska A, Gąsior-Perczak D et al (2010) The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (68Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Endokrynol Pol 61:507–511
Papotti M, Kumar U, Volante M et al (2001) Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. Clin Endocrinol 54: 641–649
Pellegriti G, Leboulleux S, Baudin E et al (2003) Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 88:1537–1542
Reubi JC, Chayvialle JA, Franc B et al (1991) Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 64:567–573
Rufini V, Calcagni ML, Baum RP (2006) Imaging of neuroendocrine tumours. Semin Nucl Med 36:228–247
Rufini V, Castaldi P, Treglia G et al (2008a) Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother 62:139–146
Rufini V, Treglia G, Perotti G et al (2008b) Role of PET in medullary thyroid carcinoma. Minerva Endocrinol 33:67–73
Rufini V, Treglia G, Castaldi P et al (2011) Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun 32:575–82
Treglia G, Calcagni ML, Rufini V et al (2011) Clinical significance of incidental focal colorectal [(18) F]FDG uptake: our experience and a review of the literature. Colorectal Dis. doi:10.1111/j.1463-1318.2011.02588.x
Versari A, Camellini L, Carlinfante G et al (2010) Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 35:321–328
Acknowledgments
This manuscript was awarded as “Best Oral Presentation” at the 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy, Bad Berka (Germany), June 23–26, 2011
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Treglia, G. et al. (2013). Comparison of Different Positron Emission Tomography Tracers in Patients with Recurrent Medullary Thyroid Carcinoma: Our Experience and a Review of the Literature. In: Baum, R., Rösch, F. (eds) Theranostics, Gallium-68, and Other Radionuclides. Recent Results in Cancer Research, vol 194. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27994-2_21
Download citation
DOI: https://doi.org/10.1007/978-3-642-27994-2_21
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-27993-5
Online ISBN: 978-3-642-27994-2
eBook Packages: MedicineMedicine (R0)